Trimetazidine in Pulmonary Artery Hypertension

You may be eligible if

• PAH patients belonging to the following subgroups of the updated Dana Point Classification Group 1
• 1. Idiopathic PAH
• 2. Heritable PAH
• 3. Drug or toxin-induced PAH
• 4. PAH associated with connective tissue disease
• 5. PAH associated to congenital heart disease with simple systemic-to-pulmonary shunt at least 1 year after surgical repair
• 6. PAH associated to HIV infection
• Documented hemodynamic diagnosis of PAH by right ventricular catheterization performed any time prior to screening
• Signed informed consent
• Patients belonging to the groups 2-5 of the updated Dana Point Classification Group
• Moderate to severe chronic pulmonary obstructive disease
• Documented left ventricular dysfunction
• Severe renal impairment (Serum creatinine \> 2.5 mg/dL)
• Patients who are receiving or have been receiving any investigational drugs within 1 month before the baseline visit
• Acute or chronic impairment (other than dyspnea) limiting the ability to comply with study requirements
• Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements
• Life expectancy less than 12 months
• Females who are lactating or pregnant or those who plan to become pregnant during the study
• Known hypersensitivity to any of the excipients of the drug formulation